世界の脳腫瘍の診断と治療市場の規模、シェア、傾向分析レポート – 業界の概要と2031年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

世界の脳腫瘍の診断と治療市場の規模、シェア、傾向分析レポート – 業界の概要と2031年までの予測

  • Healthcare IT
  • Upcoming Report
  • Sep 2024
  • Global
  • 350 ページ
  • テーブル数: 220
  • 図の数: 60

世界の脳腫瘍の診断と治療市場の規模、シェア、傾向分析レポート

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2031
Diagram 市場規模(基準年)
USD 618.28 Million
Diagram Market Size (Forecast Year)
USD 1,129.23 Million
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>世界の脳腫瘍の診断と治療市場のセグメンテーション、製品タイプ別(原発性脳腫瘍、続発性脳腫瘍)、製品分析別(染色剤とワニス、シェラック、ラッカー、その他)、診断タイプ別(CTスキャン、MRI、PET-CTスキャン、分子検査、EEG、その他)、治療タイプ別(手術、放射線療法、標的療法、化学療法、免疫療法)、エンドユーザー別(病院、外来手術センター)– 2031年までの業界動向と予測。

脳腫瘍の診断と治療市場

脳腫瘍の診断と治療市場分析

脳腫瘍の診断と治療市場は、バイオテクノロジーと分子研究の進歩に牽引されて、大幅な成長を遂げています。この分野の発展には、細胞成分の効率と保存性を高める革新的な細胞溶解技術の導入が含まれます。企業は現在、さまざまな研究ワークフローにシームレスに統合できる、より洗練された自動化システムの開発に注力しています。たとえば、マイクロ流体デバイスと音響溶解システムの導入により、研究者が細胞サンプルを取り扱い、処理する方法に革命が起こり、溶解プロセスを正確に制御し、サンプルの損失を最小限に抑えることができます。さらに、試薬配合の進歩と新しい消耗品の開発により、脳腫瘍の診断と治療技術の汎用性と有効性が向上しています。市場はまた、製薬会社とバイオテクノロジー会社による研究開発への投資の増加、および個別化医療と再生療法への重点の高まりからも恩恵を受けています。

脳腫瘍の診断と治療の市場規模

世界の脳腫瘍の診断と治療の市場規模は、2023年に6億1,828万米ドルと評価され、2024年から2031年の予測期間中に7.82%のCAGRで成長し、2031年までに11億2,923万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

脳腫瘍の診断と治療の市場動向

酵素細胞分離法の採用増加」

The brain tumor diagnosis and treatment market is growing due to advancements in imaging technologies and personalized medicine. A key trend in the market is the increasing adoption of liquid biopsy techniques for early and non-invasive diagnosis. Liquid biopsies, which analyze circulating tumor DNA (ctDNA) in the bloodstream, offer a less invasive alternative to traditional tissue biopsies. For instance, companies such as Biocept have developed liquid biopsy platforms that detect brain tumor biomarkers, allowing for earlier diagnosis and improved treatment planning. Such technology is especially beneficial for monitoring tumor progression and treatment response in real-time. Additionally, advancements in targeted therapies, such as immunotherapy and precision radiation, are providing more effective treatment options with fewer side effects. These innovations, combined with the rising incidence of brain tumors and the demand for minimally invasive diagnostic tools, are driving the growth of the brain tumor diagnosis and treatment market, improving patient outcomes and enhancing market potential.

Report Scope and Brain Tumor Diagnosis and Treatment Market Segmentation

Attributes

Brain Tumor Diagnosis and Treatment Key Market Insights

Segments Covered

  • By Product Type: Primary Brain Tumor and Secondary Brain Tumor
  • By Product Analysis: Stains and Varnishes, Shellacs, Lacquers, and Others
  • By Diagnosis Type: CT Scan, MRI, PET-CT Scan, Molecular Testing, EEG, and Others
  • By Treatment Type: Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, and Immunotherapy
  • By End- User: Hospitals and Ambulatory Surgical Centers

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Key Market Players

Pfizer Inc. (U.S.); Mayo Foundation for Medical Education and Research (MFMER) (U.S.); GE HealthCare (U.S.); AstraZeneca (U.K.); Merck & Co., Inc. (U.S.); Siemens Healthineers AG (Germany); Carestream Health (U.S.); Hitachi, Ltd. (Japan); Koninklijke Philips N.V. (Netherlands); Shimadzu Corporation (Japan); Canon Medical Systems (Japan); Eisai Co., Ltd. (Japan); Elekta (Sweden); Varian Medical Systems, Inc. (U.S.); FUJIFILM Corporation (Japan); NantOmics (U.S.); Hologic, Inc. (U.S.); Thermo Fisher Scientific Inc. (U.S.); Genentech, Inc. (U.S.); Bristol-Myers Squibb Company (U.S.).

Market Opportunities

  • Advancements in Imaging Technologies
  • Expansion of Targeted Therapies and Immunotherapies

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Brain Tumor Diagnosis and Treatment Market Definition

Brain tumor diagnosis and treatment refer to the medical processes used to identify and manage abnormal growths of cells in the brain. Diagnosis typically involves imaging technologies like MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans to detect tumors, alongside techniques such as biopsy, where a sample of the tumor is examined. Emerging methods like liquid biopsies and molecular diagnostics are also being used for non-invasive detection. Treatment encompasses various approaches depending on the tumor's type, location, and stage, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The goal is to remove or shrink the tumor while minimizing damage to healthy brain tissue and preserving neurological function.

Brain Tumor Diagnosis and Treatment Market Dynamics

Drivers

  • Rising Incidence of Brain Tumors

The rising incidence of brain tumors significantly drives the brain tumor diagnosis and treatment market. According to the Global Cancer Burden and Strategies for Cancer Control (GLOBOCAN) 2020 report, there were 19.3 million new cancer cases globally in 2020, with nearly 10.0 million deaths attributed to cancer. The increasing prevalence is influenced by factors such as environmental exposures to radiation and chemical pollutants, along with genetic predispositions. As brain tumor cases continue to rise, the demand for advanced diagnostic tools, such as high-resolution imaging and molecular diagnostics, is escalating, alongside a growing need for innovative treatment options including targeted therapies and immunotherapies. The surge in incidence directly fuels the need for continued development and adoption of cutting-edge solutions, driving growth in the brain tumor diagnosis and treatment market.

  • Growing Awareness and Screening Programs

Growing awareness and screening programs are significantly impacting the early detection and diagnosis of brain tumors, leading to increased demand for diagnostic and therapeutic solutions. Public health initiatives and educational campaigns are playing a crucial role in this shift. For instance, organizations such as the American Brain Tumor Association (ABTA) run awareness campaigns that educate public about brain tumor symptoms and the importance of early screening. Such efforts have been linked to increased participation in screening programs, such as MRI scans for individuals at higher risk or those experiencing symptoms. "Brain Tumor Awareness Month" campaign, which raises awareness about the signs of brain tumors and encourages timely medical consultation is further disseminating the awareness and screening programs. As more people become aware of the importance of early detection and seek out screening services, the demand for advanced diagnostic tools and effective treatment options rises, further propelling growth in the brain tumor diagnosis and treatment market.

Opportunities

  • Advancements in Imaging Technologies

Advancements in imaging technologies are significantly enhancing the accuracy and effectiveness of brain tumor diagnosis. For instance, the development of advanced MRI techniques, such as high-field MRI and functional MRI (fMRI), offers detailed insights into brain activity and tumor morphology, improving tumor localization and characterization. Additionally, molecular imaging technologies, including positron emission tomography (PET) with radiolabeled tracers, provide valuable information on metabolic activity and tumor cell proliferation, which is crucial for assessing tumor behavior and response to treatment. Specifically, 18F-FDG PET scans have demonstrated the ability to accurately differentiate between tumor types and evaluate treatment efficacy in brain tumor patients. Such innovations not only enhance diagnostic precision but also create opportunities for companies to develop and market cutting-edge imaging solutions, meeting the growing demand for advanced diagnostic tools in the brain tumor market.

  • Expansion of Targeted Therapies and Immunotherapies

The expansion of targeted therapies and immunotherapies is transforming the treatment landscape for brain tumors, providing new avenues for combating these challenging conditions. Targeted therapies focus on specific genetic mutations that drive tumor growth, offering a more tailored approach to treatment. For instance, temozolomide is a chemotherapy drug designed to target the DNA repair mechanisms unique to certain brain tumors, such as glioblastomas. Immunotherapies, such as CAR-T cell therapy, where T cells are engineered to recognize and attack tumor cells, showing potential in treating brain tumors such as glioblastoma by targeting cancer cells while minimizing damage to healthy tissue. Companies that invest in these advanced treatment options can capitalize on these innovations, meeting the rising demand for effective brain tumor therapies and improving patient outcomes. Consequently creating great opportunities in the market growth.

Restraints/Challenges

  • Complexity of Brain Tumors

The complexity of brain tumors presents a significant challenge in both diagnosis and treatment, as these tumors exhibit considerable variability in their types, locations, and genetic profiles. For instance, glioblastomas, a highly aggressive type of brain tumor, differ markedly from meningiomas, which generally have a better prognosis and less aggressive behavior. Glioblastomas often have diverse genetic mutations and varying responses to treatment, necessitating highly specialized diagnostic tools such as advanced MRI imaging and genetic profiling to accurately identify and understand the tumor's characteristics. Similarly, treatment plans must be tailored to each tumor's specific genetic and molecular features, requiring a multidisciplinary approach involving neurosurgeons, oncologists, and radiologists. This complexity not only complicates the development of standardized treatment protocols but also makes it challenging to implement personalized therapies consistently. Consequently hampering the brain tumor diagnosis and treatment market.

  • Limited Availability of Advanced Diagnostic and Treatment Technologies

The limited availability of advanced diagnostic and treatment technologies significantly impacts the quality of care in the brain tumor market, creating disparities between well-equipped centers and those with fewer resources. For instance, cutting-edge imaging systems such as high-field MRI scanners and PET-CT systems, which are crucial for accurate tumor localization and monitoring, are often found only in specialized centers or high-income countries. Patients in lower-income regions or less developed healthcare settings may not have access to these technologies, leading to delays in accurate diagnosis and suboptimal treatment planning. Such disparity is exemplified by the availability of novel therapeutic agents, such as targeted therapies or immunotherapies, which may only be accessible through clinical trials or in countries with advanced healthcare infrastructure.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brain Tumor Diagnosis And Treatment Market Scope

The market is segmented on the basis of product type, product analysis, diagnosis type, treatment type, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Primary Brain Tumor
    • Meningioma
    • Gliomas
    • Astrocytomas
    • Pituitary Tumors
    • Others
  • Secondary Brain Tumor

Product Analysis

  • Stains and Varnishes
  • Shellacs
  • Lacquers
  • Others

Diagnosis Type

  • CT Scan
  • MRI
  • PET-CT Scan
  • Molecular Testing
  • EEG
  • Others

Treatment Type

  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy

End User

  • Hospitals
  • Ambulatory Surgical Centers

Brain Tumor Diagnosis And Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, product analysis, diagnosis type, treatment type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the brain tumor diagnosis and treatment market, primarily due to significant research and development efforts, a high incidence of brain tumor diagnoses, and increasing awareness of treatment and management options. The region's advanced healthcare infrastructure, coupled with substantial investments in oncology research, further strengthens its dominance in this market. Additionally, growing public awareness about early diagnosis and available treatment methods contributes to the rising demand for advanced brain tumor therapies in North America.

Europe is projected to witness the highest growth rate in the brain tumor diagnosis and treatment market during the forecast period of 2024 to 2031. This growth is largely driven by government initiatives aimed at raising awareness of advanced medical technologies and improving access to cutting-edge treatments across the region. Additionally, increased investment in healthcare infrastructure and research, along with growing public awareness about early diagnosis and advanced therapies, is expected to fuel the market's expansion in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Brain Tumor Diagnosis and Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Brain Tumor Diagnosis and Treatment Market Leaders Operating in the Market Are:

  • ファイザー社(米国)
  • メイヨー医学教育研究財団 (MFMER) (米国)
  • GEヘルスケア(米国)
  • アストラゼネカ(英国)
  • メルク社(米国)
  • シーメンス ヘルシナーズ AG (ドイツ)
  • ケアストリームヘルス(米国)
  • 日立製作所(日本)
  • Koninklijke Philips NV (オランダ)
  • 島津製作所(日本)
  • キヤノンメディカルシステムズ(日本)
  • エーザイ株式会社(日本)
  • エレクタ(スウェーデン)
  • バリアンメディカルシステムズ社(米国)
  • 富士フイルム株式会社(日本)
  • ナントミクス(米国)
  • ホロジック社(米国)
  • サーモフィッシャーサイエンティフィック株式会社(米国)
  • ジェネンテック社(米国)
  • ブリストル・マイヤーズスクイブ社(米国)

脳腫瘍の診断と治療市場の最新動向

  • 2024年3月、アストラゼネカはがん治療の進歩を加速させることを目指してフュージョン・ファーマシューティカルズの買収を完了した。この買収は、化学療法や放射線療法などの従来の治療法から、患者の転帰を向上させるより革新的で的を絞ったアプローチへの移行に焦点を当てている。
  • 2024年1月、GEヘルスケアはAI駆動型イメージングおよびワークフローソリューションを専門とするMIMソフトウェアを買収しました。この買収により、GEヘルスケアはMIMの高度なAI対応ツールを腫瘍学や神経学などの分野に統合し、これらの重要なヘルスケア領域全体で診断精度を高め、治療計画を改善できるようになります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The global brain tumor diagnosis and treatment market size was valued at USD 618.28 million in 2023.
The global brain tumor diagnosis and treatment market is to grow at a CAGR of 7.82% during the forecast period of 2024 to 2031.
The major players operating in the market are Pfizer Inc. (U.S.); Mayo Foundation for Medical Education and Research (MFMER) (U.S.); GE HealthCare (U.S.); AstraZeneca (U.K.); Merck & Co., Inc. (U.S.); Siemens Healthineers AG (Germany); Carestream Health (U.S.); Hitachi, Ltd. (Japan); Koninklijke Philips N.V. (Netherlands); Shimadzu Corporation (Japan); Canon Medical Systems (Japan); Eisai Co., Ltd. (Japan); Elekta (Sweden); Varian Medical Systems, Inc. (U.S.); FUJIFILM Corporation (Japan); NantOmics (U.S.); Hologic, Inc. (U.S.); Thermo Fisher Scientific Inc. (U.S.); Genentech, Inc. (U.S.); Bristol-Myers Squibb Company (U.S.).
Rising adoption of enzymatic cell dissociation methods, rising incidence of brain tumors, and growing awareness and screening programs are major drivers of the market.
The market is segmented based on product type, product analysis, diagnosis type, treatment type, and end-user. On the basis of product type, the market is segmented into primary brain tumor and secondary brain tumor. On the basis of product analysis, the market is segmented into stains and varnishes, shellacs, lacquers, and others. On the basis of diagnosis type, the market is segmented into CT scan, MRI, PET-CT scan, molecular testing, EEG, and others. On the basis of treatment type, the market is segmented into surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy. On the basis of end-user, the market is segmented into hospitals and ambulatory surgical centers.